BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18537549)

  • 1. Cancer neovascularization and proinflammatory microenvironments.
    Furuya M; Yonemitsu Y
    Curr Cancer Drug Targets; 2008 Jun; 8(4):253-65. PubMed ID: 18537549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. III. Angiogenesis: complexity of tumor vasculature and microenvironment.
    Furuya M; Yonemitsu Y; Aoki I
    Curr Pharm Des; 2009; 15(16):1854-67. PubMed ID: 19519428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
    Ferrara N
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
    Reinacher-Schick A; Pohl M; Schmiegel W
    Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor angiogenesis and anti-angiogenic therapies.
    Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
    Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges for patient selection with VEGF inhibitors.
    Longo R; Gasparini G
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):151-70. PubMed ID: 17370072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor inhibitors in colon cancer.
    Díaz-Rubio E
    Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer strategies involving the vasculature.
    Heath VL; Bicknell R
    Nat Rev Clin Oncol; 2009 Jul; 6(7):395-404. PubMed ID: 19424102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of tumor neovascularization.
    Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ishikura H
    Vasc Health Risk Manag; 2005; 1(4):277-90. PubMed ID: 17315600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
    Homsi J; Daud AI
    Cancer Control; 2007 Jul; 14(3):285-94. PubMed ID: 17615535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF as a therapeutic target in cancer.
    Ferrara N
    Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF and colon cancer growth beyond angiogenesis: does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism?
    Ahluwalia A; Jones MK; Matysiak-Budnik T; Tarnawski AS
    Curr Pharm Des; 2014; 20(7):1041-4. PubMed ID: 23755727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.